— Know what they know.
Not Investment Advice

Financial News

Sentiment -79.0 4036 articles 1863 bullish 1369 bearish Full Index →
📰

Stock futures roar higher as Trump calls off Iran strike ultimatum

Per Yahoo! Finance: US stocks were poised for yet another bruising day on Monday as Iran and President Trump traded war threats, raising tensions...
📰

The Market Is Panicking About Shopify and AI -- Here's Why I'm Buying the Dip

Don't let AI disruption fears get in the way of this excellent long-term opportunity.
Dow futures jump 1,100 points as Trump signals pause in Iran

Dow futures jump 1,100 points as Trump signals pause in Iran strikes

US stock futures witnessed a sharp jump on Monday after US President Donald Trump said Washington and Tehran had held “productive” talks over the...
📰

Shift4 Payments’ (FOUR) Revenue Per Share Increased by 122% Over the Past Three Years - Yahoo Finance

Shift4 Payments’ (FOUR) Revenue Per Share Increased by 122% Over the Past Three Years  Yahoo Finance
📰

Shift4 Payments’ (FOUR) Revenue Per Share Increased by 122% Over the Past Three Years

Marram Investment Management, an outsourced long-term investment solutions provider, released its fourth-quarter investor letter. A copy of the...
Trump Postpones Iran Energy Target Strikes for Five Days

Trump Postpones Iran Energy Target Strikes for Five Days

President Donald Trump ordered the Pentagon to postpone military strikes against Iranian power plants and energy infrastructure for a five-day...
Trump Says U.S. And Iran Held ‘Productive Conversations’ To

Trump Says U.S. And Iran Held ‘Productive Conversations’ To End Hostilities

The president also said he has ordered the Pentagon to postpone military strikes on Iran’s power plants for at least 5 days, extending a deadline he...
📰

Oil tumbles after Trump postpones U.S. strikes against Iran energy infrastructure for five days

Oil prices tumbled Monday after President Donald Trump said the U.S. and Iran had productive talks, leading him to order a halt on strikes against...
📰

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she...
📰

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she...
📰

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second...
📰

SL Green Realty Corp. Announces Annual Ordinary Dividend of $2.47 per Share

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan's largest office landlord, announced today that its...
Ex-Goldman Banker’s AI Chip Company Secures SoftBank Funding

Ex-Goldman Banker’s AI Chip Company Secures SoftBank Funding

Kandou AI, an artificial-intelligence chip company led by a former Goldman Sachs Group Inc. managing director, raised $225 million from investors...
EndoCyclic Therapeutics Announces FDA Clearance of Investiga

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis

IRVINE, Calif., March 23, 2026 /PRNewswire/ -- EndoCyclic Therapeutics, a biopharmaceutical company developing precision peptide therapeutics and...
📰

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical...
📰

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing...
📰

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025
HyBryte™ Treatment Results to be Presented at US Cutaneous L

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc....
EndoCyclic Therapeutics Announces FDA Clearance of Investiga

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis

IRVINE, Calif., March 23, 2026 /PRNewswire/ -- EndoCyclic Therapeutics, a biopharmaceutical company developing precision peptide therapeutics and...
« Prev 1 385 386 387 388 389 489 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms